Last reviewed · How we verify
Monovalent Influenza Vaccine
Monovalent Influenza Vaccine is a Biologic drug developed by MedImmune LLC. It is currently FDA-approved.
The Monovalent Influenza Vaccine, marketed by MedImmune LLC, holds a position in the influenza vaccine market with a key composition patent expiring in 2028. A key strength of the vaccine is its established market presence and regulatory approval. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Monovalent Influenza Vaccine |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE1)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults (PHASE1)
- Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59 (PHASE2)
- Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults (PHASE1, PHASE2)
- Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older (PHASE1)
- Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (PHASE1)
- Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monovalent Influenza Vaccine CI brief — competitive landscape report
- Monovalent Influenza Vaccine updates RSS · CI watch RSS
- MedImmune LLC portfolio CI
Frequently asked questions about Monovalent Influenza Vaccine
What is Monovalent Influenza Vaccine?
Who makes Monovalent Influenza Vaccine?
What development phase is Monovalent Influenza Vaccine in?
Related
- Manufacturer: MedImmune LLC — full pipeline
- Compare: Monovalent Influenza Vaccine vs similar drugs
- Pricing: Monovalent Influenza Vaccine cost, discount & access